<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1134-8046</journal-id>
<journal-title><![CDATA[Revista de la Sociedad Española del Dolor]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Soc. Esp. Dolor]]></abbrev-journal-title>
<issn>1134-8046</issn>
<publisher>
<publisher-name><![CDATA[Inspira Network Group, S.L ]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1134-80462020000300004</article-id>
<article-id pub-id-type="doi">10.20986/resed.2020.3749/2019</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Consumo de fármacos utilizados en el tratamiento del dolor musculoesquelético en una cohorte de trabajadores manuales de Zaragoza (España)]]></article-title>
<article-title xml:lang="en"><![CDATA[Consumption of drugs used for the treatment of musculoskeletal pain in a cohort of manual workers in Zaragoza (Spain)]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gaspar Calvo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lallana Álvarez]]></surname>
<given-names><![CDATA[M J]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Malo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Servicio Aragonés de Salud Centro de Salud Las Fuentes Norte ]]></institution>
<addr-line><![CDATA[Zaragoza ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Servicio Aragonés de Salud Atención Primaria Sector Zaragoza III Servicio de Farmacia]]></institution>
<addr-line><![CDATA[Zaragoza ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad de Zaragoza Departamento de Medicina Preventiva y Salud Pública ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Instituto de Investigación Sanitaria de Aragón  ]]></institution>
<addr-line><![CDATA[Zaragoza ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<volume>27</volume>
<numero>3</numero>
<fpage>150</fpage>
<lpage>159</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1134-80462020000300004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1134-80462020000300004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1134-80462020000300004&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: La alta prevalencia de enfermedades musculoesqueléticas (EME) en determinados grupos de población puede condicionar que el consumo de antiinflamatorios no esteroideos (AINE) sea elevado. El presente estudio pretende identificar a los consumidores continuados de AINE en una cohorte de trabajadores que realizan fundamentalmente tareas de tipo manual, analizando el uso que hacen de otros fármacos indicados en el tratamiento del dolor musculoesquelético (DME).  Material y métodos: Estudio observacional retrospectivo, en el que se han analizado los datos, recogidos en la base de consumo farmacéutico Farmasalud, de todos los sujetos de la cohorte AWHS (Aragon Workers Health Study), que presentaron al menos una receta de un AINE durante el año 2016. Se ha calculado la tasa de utilización de AINE, así como el número de dosis diarias definidas (DDD) por 1000 habitantes por día (DHD). Se han identificado los consumidores continuados como aquellos que utilizaron 182 DDD o más. Para este grupo de consumo, se han analizado otros fármacos prescritos que suelen asociarse al tratamiento del DME.  Resultados: La tasa de utilización de AINE en la cohorte AWHS en 2016 fue del 41,6 % (IC 95 %: 40,1-42,7 %), siendo mayor en mujeres (47,0 %, IC 95 %: 41,9-52,1 %). El 5,7 % de los usuarios de AINE se consideraron consumidores continuados. Dentro de este grupo, el etoricoxib fue el AINE más utilizado (4,9 DHD), seguido de ibuprofeno (4,0 DHD). En cuanto a otros fármacos relacionados con el tratamiento del dolor musculoesquelético, la tasa de prescripción de tramadol en los consumidores continuados de AINE fue 24,2 % (IC 95 %: 16,9-23,3 %) y la de benzodiazepinas 3,0 % (IC 95 %: 0,1-6,0 %).  Conclusiones: El consumo de AINE en la cohorte AWHS fue más elevado que el reportado en la población general. Los consumidores continuados utilizaron preferentemente AINE con un menor riesgo cardiovascular. La tasa de consumo de opioides débiles, en los consumidores continuados de AINE, fue elevada.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction: The high prevalence of musculoskeletal diseases (MSDs) in certain populaion groups may cause a high consumption of non steroideal antiinflamatory drugs (NSAIDs). The present study aims to identify the continuous consumers of NSAIDs in a cohort of workers, who mainly perform manual tasks, analyzing the use of other drugs prescribed for the treatment of musculoskeletal pain (MSP).  Material and methods: Observational retrospective study. It has been analyzed data of all subjects, included on the AWHS (Aragon Workers Health Study) cohort, who received at least one NSAID prescription during 2016. It has been calculated the rate of use of NSAID, as well as the number of DDD per 1000 inhabitants per day (DHD). It has been identified continuous consumers, as those who used 182 defined daily dose (DDD) or more. For this group, it has been analyzed all prescriptions including other drugs used to treat MSP.  Results: The rate of use of NSAIDs in the AWHS cohort in 2016 was 41.6% (95% CI: 40.1%-42.7%), being higher in women (47.0%, 95% CI: 41.9%-52.1%). 5.7% of NSAID users were continuous consumers. Among them, etoricoxib was the most used NSAIDs (4,9 DHD), followed by ibuprofen (4,0 DHD). Refering to other drugs prescribed for MSP, the prescription rate of tramadol for continuous consumers was 24.2% (95% CI: 16.9%-23.3%) and benzodiazepines 3.0% (95% CI: 0.1%-6.0%).  Conclusions: NSAID consumption in the AWHS cohort appears to be higher than in general population. Continuous consumers preferably used NSAIDs with lower cardiovascular risk. The consumption rate of weak opioids was high for continuous users.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Antiinflamatorios no esteroideos]]></kwd>
<kwd lng="es"><![CDATA[analgésicos opioides]]></kwd>
<kwd lng="es"><![CDATA[enfermedades musculoesqueléticas]]></kwd>
<kwd lng="es"><![CDATA[tratamiento farmacológico dolor crónico]]></kwd>
<kwd lng="en"><![CDATA[Non-steroidal anti-inflamatory drugs]]></kwd>
<kwd lng="en"><![CDATA[analgesics]]></kwd>
<kwd lng="en"><![CDATA[opioids]]></kwd>
<kwd lng="en"><![CDATA[musculoskeletal diseases]]></kwd>
<kwd lng="en"><![CDATA[chronic pain pharmacological therapy]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<collab>Instituto Nacional de Estadística</collab>
<source><![CDATA[Encuesta Nacional de Salud]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<collab>Departamento de Medicamentos de Uso Humano de la AEMPS</collab>
<source><![CDATA[Utilización de medicamentos atiinflamatorios no esteroideos en España durante el periodo 2013-2016]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Agencia Española de Utilización de Medicamentos y productos sanitarios, Ministerio de Sanidad, Seguridad Social e Igualdad]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<collab>Ministerio de Sanidad servicios sociales e igualdad</collab>
<source><![CDATA[Documento Marco para la mejora del abordaje del dolor en el SNS]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harirforoosh]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Asghar]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Jamali]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications]]></article-title>
<source><![CDATA[J Pharm Pharm Sci]]></source>
<year>2013</year>
<volume>16</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>821-47</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arfè]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Scotti]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Varas-Lorenzo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Nicotra]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Zambon]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kollhorst]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2016</year>
<volume>354</volume>
<page-range>i4857</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baigent]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bhala]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Emberson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Merhi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Abramson]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Arber]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: Meta-analyses of individual participant data from randomised trials]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2013</year>
<volume>382</volume>
<numero>9894</numero>
<issue>9894</issue>
<page-range>769-79</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McGettigan]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Henry]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular risk and inhibition of cyclooxygenase: A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2006</year>
<volume>296</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>1633-44</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schmidt]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lamberts]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Olsen]]></surname>
<given-names><![CDATA[AM Schjerning]]></given-names>
</name>
<name>
<surname><![CDATA[Fosbøll]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Niessner]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tamargo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2016</year>
<volume>37</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>1015-23</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olsen]]></surname>
<given-names><![CDATA[AM Schjerning]]></given-names>
</name>
<name>
<surname><![CDATA[Gislason]]></surname>
<given-names><![CDATA[GH]]></given-names>
</name>
<name>
<surname><![CDATA[McGettigan]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Fosbøl]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Sørensen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hansen]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of NSAID Use With Risk of Bleeding and Cardiovascular Events in Patients Receiving Antithrombotic Therapy After Myocardial Infarction]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2015</year>
<volume>313</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>805-14</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lapi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Azoulay]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Yin]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Nessim]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Suissa]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2013</year>
<volume>346</volume>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moore]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Pollack]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Butkerait]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse drug reactions and drug-drug interactions with over-the-counter NSAIDs]]></article-title>
<source><![CDATA[Ther Clin Risk Manag]]></source>
<year>2015</year>
<volume>11</volume>
<page-range>1061-75</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Helin-Salmivaara]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Huupponen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Virtanen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lammela]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Klaukka]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frequent prescribing of drugs with potential gastrointestinal toxicity among continuous users of non-steroidal anti-inflammatory drugs]]></article-title>
<source><![CDATA[Eur J Clin Pharmacol]]></source>
<year>2005</year>
<volume>61</volume>
<numero>5-6</numero>
<issue>5-6</issue>
<page-range>425-31</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez Serrano]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Tenias Burillo]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Arias Arias]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz Carreras]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
<name>
<surname><![CDATA[Valenzuela Gámez]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Riesgo cardiovascular asociado al consumo de antiinflamatorios no esteroideos Estudio de cohortes retrospectivo en un área de salud, 2008-2012]]></article-title>
<source><![CDATA[Rev Esp Salud Publica]]></source>
<year>2015</year>
<volume>89</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abajo]]></surname>
<given-names><![CDATA[FJ de]]></given-names>
</name>
<name>
<surname><![CDATA[Gil]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[García Poza]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bryant]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Oliva]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Timoner]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk of nonfatal acute myocardial infarction associated with non-steroidal antiinflammatory drugs, non-narcotic analgesics and other drugs used in osteoarthritis: A nested case-control study]]></article-title>
<source><![CDATA[Pharmacoepidemiol Drug Saf]]></source>
<year>2014</year>
<volume>23</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1128-38</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="">
<collab>Organización Mundial de la Salud</collab>
<source><![CDATA[Alivio del dolor en el cáncer]]></source>
<year>1996</year>
<publisher-loc><![CDATA[Ginebra ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="">
<source><![CDATA[Trastornos musculoesqueléticos - Salud y seguridad en el trabajo - EU-OSHA]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Casasnovas]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Alcaide]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Civeira]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Guallar]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ibañez]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Borreguero]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aragon workers' health study - design and cohort description]]></article-title>
<source><![CDATA[BMC Cardiovasc Disord]]></source>
<year>2012</year>
<volume>12</volume>
<page-range>45</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="">
<collab>WHOCC</collab>
<source><![CDATA[ATC/DDD Index]]></source>
<year></year>
<publisher-loc><![CDATA[Oslo ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aranguren Ruiz]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Elizondo Rivas]]></surname>
<given-names><![CDATA[GAAA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consideraciones de seguridad de los AINE]]></article-title>
<source><![CDATA[Boletín Inf Farmacoter Navarra]]></source>
<year>2016</year>
<volume>24</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>1-13</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pinilla García]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Almodóvar Molina]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Galiana Blanco]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Hervás River]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Zimmermann Verdejo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Encuesta Nacional de Condiciones de Trabajo. 2015 6a EWCS - España]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Instituto Nacional de Seguridad e Higiene en el Trabajo (INSHT), Ministerio de Empleo y Seguridad Social]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="">
<source><![CDATA[SEMERGEN | Sociedad Española de Médicos de Atención Primaria]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="book">
<collab>Agencia Española de Medicamentos y Productos Sanitarios AEMPS</collab>
<source><![CDATA[Seguridad Cadiovascular de los AINE tradicionales: conclusiones de la revisión de los últimos estudios publicados]]></source>
<year>2012</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Ministerio de Sanidad SS e I]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Richette]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Latourte]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Frazier]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety and efficacy of paracetamol and NSAIDs in osteoarthritis: which drug to recommend?]]></article-title>
<source><![CDATA[Expert Opin Drug Saf]]></source>
<year>2015</year>
<volume>14</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1259-68</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="">
<source><![CDATA[OARSI Guidelines | Osteoarthritis Research Society International (OARSI)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="book">
<collab>Fundació Institut Catalá de Farmacologia</collab>
<source><![CDATA[Riscos associats a l'ús concomitant d'opioides i benzodiazepines]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Barcelona ]]></publisher-loc>
<publisher-name><![CDATA[Sevei Catalá de la Salut CatSalut]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="book">
<collab>VVAA</collab>
<source><![CDATA[Guía de consenso para el buen uso de analgésicos opioides]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Valencia ]]></publisher-loc>
<publisher-name><![CDATA[Sociedad Científica Española de Estudios sobre el Alcohol, el Alcoholismo y las otras Toxicomanías]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios</collab>
<source><![CDATA[Utilización de medicamentos opioides en España durante el periodo 2008-2015]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gouveia]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Rodrigues]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ramiro]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Eusébio]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Machado]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Canhao]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Use of Analgesic and Other Pain-Relief Drugs to Manage Chronic Low Back Pain: Results from a National Survey]]></article-title>
<source><![CDATA[Pain Pract]]></source>
<year>2017</year>
<volume>17</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>353-65</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dowell]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Haegerich]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Chou]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CDC guideline for prescribing opioids for chronic pain-United States, 2016]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2016</year>
<volume>315</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>1624-45</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cadogan]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Ryan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cahir]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bradley]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Bennett]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Benzodiazepine and Z-drug prescribing in Ireland: analysis of national prescribing trends from 2005 to 2015]]></article-title>
<source><![CDATA[Br J Clin Pharmacol]]></source>
<year>2018</year>
<volume>84</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1354-63</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Petitjean]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ladewig]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Meier]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Amrein]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Wiesbeck]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Benzodiazepine prescribing to the Swiss adult population: results from a national survey of community pharmacies]]></article-title>
<source><![CDATA[Int Clin Psychopharmacol]]></source>
<year>2007</year>
<volume>22</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>292-8</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bachhuber]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Hennessy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cunningham]]></surname>
<given-names><![CDATA[CO]]></given-names>
</name>
<name>
<surname><![CDATA[Starrels]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Increasing Benzodiazepine Prescriptions and Overdose Mortality in the United States, 1996-2013]]></article-title>
<source><![CDATA[Am J Public Health]]></source>
<year>2016</year>
<volume>106</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>686-8</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haro]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Palacin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Vilagut]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bernal]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Luque]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalencia y factores asociados de los trastornos mentales en España: resultados del estudio ESEMeD-España]]></article-title>
<source><![CDATA[Med Clin]]></source>
<year>2006</year>
<volume>126</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>445-51</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<collab>Cochrane Database</collab>
<article-title xml:lang=""><![CDATA[Analgésicos orales de venta sin receta (SPM) para el dolor agudo: un resumen de revisiones Cochrane]]></article-title>
<source><![CDATA[Cochrane Database of Systematic Reviews]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stosic]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Dunagan]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Palmer]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Fowler]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Adams]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Responsible self-medication: perceived risks and benefits of over-the-counter analgesic use]]></article-title>
<source><![CDATA[Int J Pharm Pract]]></source>
<year>2011</year>
<volume>19</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>236-45</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="">
<collab>Ministerio de Sanidad, Consumo y Bienestar Social</collab>
<source><![CDATA[Portal Estadístico del SNS - Encuesta Nacional de Salud de España]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Malo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Poblador-Plou]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Prados-Torres]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lallana]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Laguna-Berna]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rabanaque]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Poor congruence with guidelines in the use of antibiotics for acute bronchitis: a descriptive study based on electronic health records]]></article-title>
<source><![CDATA[Fam Pract]]></source>
<year>2016</year>
<volume>33</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>471-5</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lallana Álvarez]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Feja Solana]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Malo Fumanal]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Abad Diez]]></surname>
<given-names><![CDATA[JMBL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Variabilidad de la prescripción de antibióticos en Atención Primaria de los Sectores Sanitarios de Aragón]]></article-title>
<source><![CDATA[Rev Esp Salud Pública]]></source>
<year>2012</year>
<volume>86</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>627-35</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muñoz Giménez]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Mora Corberá]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamientos farmacológicos de la enfemedad de Alzheimer Estudio comparativo de uso de la Comunidad de Aragón]]></article-title>
<source><![CDATA[Farm Prof]]></source>
<year>2010</year>
<volume>24</volume>
<page-range>60-6</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Villar-Fernández]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Bjerrum]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Feja]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rabanaque]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Variability in the Prescription of Cholinesterase Inhibitors and Memantine]]></article-title>
<source><![CDATA[Dement Geriatr Cogn Disord]]></source>
<year>2009</year>
<volume>28</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>373-9</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
